Announcement of Biotech on its subsidiary’s acquisition of new veterinary drug registration certificate
Securities code: 600201 Securities abbreviation: Biology Shares Announcement number: Lin 2026-005
Jinyu Biotechnology Co., Ltd.
Announcement on Subsidiary Obtaining New Veterinary Drug Registration Certificate
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
According to the national "Veterinary Drug Administration Regulations" and the "Veterinary Drug Registration Measures", after review by the Ministry of Agriculture and Rural Affairs, the dual inactivated vaccine (A-VII strain + GPVP3/Bac strain) for Newcastle disease of geese and gosling plague jointly developed by Jinyu Youbang Biotechnology (Jiangsu) Co., Ltd. (hereinafter referred to as "Jinyu Youbang"), a wholly-owned subsidiary of Jinyu Biotechnology Co., Ltd. (hereinafter referred to as the "Company") and other units is approved as a new veterinary drug. The details are as follows:
1. Basic situation of new veterinary drug products
New veterinary drug name: Newcastle disease of geese and double inactivated vaccine of gosling plague (A-VII strain + GPVP3/Bac strain) Registration classification: Category III
New Veterinary Drug Registration Certificate Number: (2026) New Veterinary Drug Certificate No. 44
Research units: Jinyuyoubang Biotechnology (Jiangsu) Co., Ltd., Yangzhou University, Zhongchong Cigna Biotechnology Taizhou Co., Ltd., Guangdong Yongshun Biopharmaceutical Co., Ltd.
Function and use: Used to prevent Newcastle disease in geese and gosling plague. The immunity generation period of breeding geese is 21 days after the second vaccination, and the immunity period is 5 months. The passive immunity period of goslings is 20 days.
Usage and dosage: Injection into chest muscle. Breeding geese were injected with 1.0ml 5 weeks before calving, and boosted once with the same dose 3 weeks later.
Storage and validity period: Store at 2-8℃, validity period is 12 months.
2. Research and Development of New Veterinary Drug Products
Newcastle disease and gosling plague virus are two important diseases that harm the waterfowl industry, causing huge losses to the poultry industry. The dual inactivated vaccine against Newcastle disease in geese and plague in goslings (A-VII strain + GPVP3/Bac strain) jointly developed by the company and other units adopts embryotoxin production technology and baculovirus expression technology. The insect expression system can be used to express proteins efficiently. It has the advantages of good immunogenicity, rapid antibody production, and can be prepared on a large scale. The company was unable to obtain market sales data for similar products from public sources.
3. Relevant procedures before launch of new veterinary drug products
Before the above-mentioned new veterinary drug products are put on the market, Jinyu Youbang will carry out product approval number application and review related work in accordance with the requirements of the "Veterinary Drug Administration Regulations" and "Veterinary Drug Product Approval Number Management Measures". After obtaining the veterinary drug product approval number, the new veterinary drug product will be eligible for marketing.
4. Impact of new veterinary drug products on the company
The successful approval of this product further enriches the company's waterfowl vaccine product matrix, meets the urgent needs of breeding customers for "one shot for multiple defenses" and efficient and simplified immunization procedures. It helps enhance the stickiness of breeding customers and enhances the company's market competitiveness in the field of waterfowl vaccines.
Announcement is hereby made.
Jinyu Biotechnology Co., Ltd.
board of directors
March 27, 2026